Bryggargatan 10
Stockholm 111 21
Sweden
46 7 62 19 37 38
https://www.ibtherapeutics.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 8
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Staffan Stromberg Ph.D. | Chief Executive Officer | 5.33M | N/A | 1967 |
Ms. Maria Ekdahl | Chief Financial Officer | N/A | N/A | 1973 |
Mr. Anders Kronström M.B.A., M.S. | Chief Operating Officer | 500k | N/A | 1967 |
Dr. Thomas J. Schnitzer M.D., Ph.D. | Chief Scientific Officer | N/A | N/A | N/A |
Mr. Sanjiv Sharma M.B.A. | Head of Medical Affairs | N/A | N/A | 1957 |
Prof. Jonas Rastad M.D., Ph.D. | Chief Medical Officer | N/A | N/A | 1950 |
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies `to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants. In addition, its drug candidates include IBP-1118 to prevent retinopathy of prematurity that causes blindness in premature babies; and IBP-1122, indicated to eliminate vancomycin resistant enterococci that cause antibiotic resistant hospital infections. The company was incorporated in 2011 and is based in Stockholm, Sweden.
Infant Bacterial Therapeutics AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.